Pfizer Ducks FCA Suit Over Lipitor Marketing Practices

Law360, New York (November 15, 2012, 5:41 PM EST) -- A New York federal judge on Wednesday threw out an 8-year-old False Claims Act suit from a former Pfizer Inc. medical director claiming the company engaged in off-label marketing of its statin Lipitor, ruling that federal cholesterol guidelines are meant to be advisory rather than restrictive limitations.

In dismissing qui tam plaintiff Jesse Polansky's fifth amended complaint, U.S. District Judge Brian M. Cogan said that the National Cholesterol Education Program guidelines fall within the standard, noncompulsory definition of the term "guidelines." As long as Pfizer is...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

United States of America et al v. Pfizer, Inc.


Case Number

1:04-cv-00704

Court

New York Eastern

Nature of Suit

Other Statutory Actions

Judge

Brian M. Cogan

Date Filed

February 19, 2004

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.